Termination notice effective period.

No definition available.

Name:	tvrd_AgreementTerminationNoticeEffectivePeriod
Namespace Prefix:	tvrd_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of milestone payment receivable under the collaboration and license agreement.

+ References

No definition available.

+ Details

Name:	tvrd_CollaborationAndLicensingAgreementMilestonePaymentReceivable
Namespace Prefix:	tvrd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Number of days to terminate agreement upon material breach.

+ References

No definition available.

+ Details

Name:	tvrd_NumberOfDaysToTerminateAgreementUponMaterialBreach
Namespace Prefix:	tvrd_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of net profits sharing.

+ References

No definition available.

+ Details

Name:	tvrd_PercentageOfNetProfitsSharing
Namespace Prefix:	tvrd_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of potential milestone payment of common stock investment.

+ References

No definition available.

+ Details

Name:	tvrd_PotentialMilestonePayment
Namespace Prefix:	tvrd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of potential payment upon achievement of certain sales-based milestones.

+ References

No definition available.

+ Details

Name:	tvrd_PotentialSalesMilestonePayment
Namespace Prefix:	tvrd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 14
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

+ Details

Name:	us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	dei_LegalEntityAxis=tvrd_CaraTherapeuticsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=tvrd_ViforFreseniusMedicalCareRenalPharmaLtdAgreementNo1Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=tvrd_ViforFreseniusMedicalCareRenalPharmaLtdAgreementNo2Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=tvrd_LicenseAgreementWithMaruishiPharmaceuticalCo.LtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=tvrd_CslViforMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=tvrd_ViforFreseniusMedicalCareRenalPharmaLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration and Licensing Agreements - Additional Information (Detail) - Cara Therapeutics, Inc. - USD ($) $ in Thousands		1 Months Ended		12 Months Ended
	May 17, 2018	Oct. 31, 2020	May 31, 2018	Dec. 31, 2024	Dec. 31, 2023
Collaboration and Licensing Agreements:
Net proceeds from sales of common stock under open market sales agreement					$ 1,117
Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 1 [Member]
Collaboration and Licensing Agreements:
Percentage of net profit sharing		60.00%
Potential sales-based milestone payments		$ 240,000
Number of days to terminate agreement				60 days
Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 2 [Member]
Collaboration and Licensing Agreements:
Percentage of net profit sharing			50.00%
License Agreement with Maruishi Pharmaceutical Co. Ltd [Member]
Collaboration and Licensing Agreements:
Earned milestone payment					$ 1,449
Affiliated Entity \| Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 1 [Member]
Collaboration and Licensing Agreements:
Percentage of net profit sharing		40.00%
Affiliated Entity \| CSL Vifor \| Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 1 [Member]
Collaboration and Licensing Agreements:
Percentage of net profit sharing		40.00%
Affiliated Entity \| Vifor Fresenius Medical Care Renal Pharma Ltd \| Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 2 [Member]
Collaboration and Licensing Agreements:
Number of days to terminate agreement	60 days
Termination notice effective period	12 months
Affiliated Entity \| Vifor Fresenius Medical Care Renal Pharma Ltd \| Maximum [Member] \| Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 2 [Member]
Collaboration and Licensing Agreements:
Potential milestone payments	$ 440,000